NCT07174908 2026-03-03
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
InxMed (Shanghai) Co., Ltd.
Phase 3 Recruiting
InxMed (Shanghai) Co., Ltd.
Merck Sharp & Dohme LLC
Innovent Biologics (Suzhou) Co. Ltd.